Loading...
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
The pace of therapeutic drug development in multiple myeloma has reached unprecedented levels, with five regulatory approvals for relapsed and/or refractory disease of either new drugs or new regimens in 2015, and one already in 2016, while still others are anticipated. This has provided a wide arra...
Na minha lista:
| Udgivet i: | Clin Cancer Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5705234/ https://ncbi.nlm.nih.gov/pubmed/28151712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0861 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|